首页 > 最新文献

Current Opinion in Gastroenterology最新文献

英文 中文
Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis. 轻度非坏死性急性胰腺炎后患糖尿病的风险和决定因素。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-26 DOI: 10.1097/MOG.0000000000001055
Ariana Pichardo-Lowden, Mark O Goodarzi, Guru Trikudanathan, Jose Serrano, Kathleen M Dungan

Purpose of review: Diabetes mellitus (DM) is relatively common following acute pancreatitis (AP), even after mild acute pancreatitis (MAP), the most frequent AP presentation, in which there is no overt beta cell injury. Post-AP related diabetes is widely misdiagnosed, resulting in potentially inappropriate treatment and worse outcomes than type 2 diabetes (T2D). Thus, it is important to understand risk across the spectrum of AP severity.

Recent findings: Biological mechanisms are unclear and may include local and systemic inflammation leading to beta cell dysfunction and insulin resistance, altered gut barrier and/or gut peptides and possibly islet autoimmunity, though no studies have specifically focused on MAP. While studies examining clinical risk factors on MAP exclusively are lacking, there are studies which include MAP. These studies vary in scientific rigor, approaches to rule out preexisting diabetes, variable AP severity, diagnostic testing methods, and duration of follow-up. Overall, disease related factors, including AP severity, as well as established T2D risk factors are reported to contribute to the risk for DM following AP.

Summary: Though numerous studies have explored risk factors for DM after AP, few studies specifically focused on MAP, highlighting a key knowledge gap that is relevant to the majority of patients with AP.

综述的目的:糖尿病(DM)在急性胰腺炎(AP)后相对常见,即使是在轻度急性胰腺炎(MAP)后也是如此,轻度急性胰腺炎是最常见的急性胰腺炎表现,其中没有明显的β细胞损伤。与急性胰腺炎相关的糖尿病被广泛误诊,可能导致治疗不当和比 2 型糖尿病(T2D)更糟糕的结果。因此,了解 AP 严重程度范围内的风险非常重要:生物机制尚不清楚,可能包括导致β细胞功能障碍和胰岛素抵抗的局部和全身性炎症、肠道屏障和/或肠道肽的改变以及可能的胰岛自身免疫,但没有研究专门针对MAP。虽然缺乏专门针对 MAP 临床风险因素的研究,但有一些研究包括了 MAP。这些研究在科学严谨性、排除原有糖尿病的方法、不同的 AP 严重程度、诊断测试方法和随访时间等方面各不相同。总之,包括 AP 严重程度在内的疾病相关因素以及已确定的 T2D 风险因素据报道都会导致 AP 后发生 DM 的风险。总结:尽管有许多研究探讨了 AP 后发生 DM 的风险因素,但很少有研究专门关注 MAP,这凸显了与大多数 AP 患者相关的关键知识缺口。
{"title":"Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis.","authors":"Ariana Pichardo-Lowden, Mark O Goodarzi, Guru Trikudanathan, Jose Serrano, Kathleen M Dungan","doi":"10.1097/MOG.0000000000001055","DOIUrl":"10.1097/MOG.0000000000001055","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diabetes mellitus (DM) is relatively common following acute pancreatitis (AP), even after mild acute pancreatitis (MAP), the most frequent AP presentation, in which there is no overt beta cell injury. Post-AP related diabetes is widely misdiagnosed, resulting in potentially inappropriate treatment and worse outcomes than type 2 diabetes (T2D). Thus, it is important to understand risk across the spectrum of AP severity.</p><p><strong>Recent findings: </strong>Biological mechanisms are unclear and may include local and systemic inflammation leading to beta cell dysfunction and insulin resistance, altered gut barrier and/or gut peptides and possibly islet autoimmunity, though no studies have specifically focused on MAP. While studies examining clinical risk factors on MAP exclusively are lacking, there are studies which include MAP. These studies vary in scientific rigor, approaches to rule out preexisting diabetes, variable AP severity, diagnostic testing methods, and duration of follow-up. Overall, disease related factors, including AP severity, as well as established T2D risk factors are reported to contribute to the risk for DM following AP.</p><p><strong>Summary: </strong>Though numerous studies have explored risk factors for DM after AP, few studies specifically focused on MAP, highlighting a key knowledge gap that is relevant to the majority of patients with AP.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"396-403"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ideal strategy for nonvariceal upper gastrointestinal bleeding. 治疗非静脉性上消化道出血的理想策略。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MOG.0000000000001043
Robert T Kavitt, Ian M Gralnek

Purpose of review: Over 300 000 hospital admissions in the United States each year are due to patients with upper gastrointestinal (GI) bleeding (UGIB). Common etiologies of nonvariceal UGIB include peptic ulcers, mucosal erosions of the esophagus, stomach or duodenum, Mallory-Weiss tears, Dieulafoy lesions, upper GI tract malignancy, or other etiology.

Recent findings: Peptic ulcers classified as Forrest Ia, Ib, or IIa require endoscopic hemostasis, while IIb ulcers may be considered for endoscopic clot removal with endoscopic treatment of any underlying major stigmata. Endoscopic hemostasis for ulcers classified as Forrest IIc or III is not advised due to the low risk of recurrent bleeding. Endoscopic hemostasis in ulcer bleeding can be achieved using injection, thermal, and/or mechanical modalities.

Summary: This review focuses on the currently recommended endoscopic therapies of patients presenting with acute nonvariceal upper gastrointestinal hemorrhage.

审查目的:在美国,每年有 30 多万上消化道出血(UGIB)患者入院治疗。非溃疡性上消化道出血的常见病因包括消化性溃疡、食道、胃或十二指肠粘膜糜烂、Mallory-Weiss 撕裂、Dieulafoy 病变、上消化道恶性肿瘤或其他病因:消化性溃疡分类为 Forrest Ia、Ib 或 IIa,需要进行内镜下止血,而 IIb 溃疡可考虑在内镜下清除血块,并在内镜下治疗任何潜在的主要病灶。由于复发性出血的风险较低,不建议对福瑞斯特 IIc 或 III 级溃疡进行内镜下止血。溃疡出血的内镜止血可通过注射、热敷和/或机械方式实现。摘要:本综述重点介绍目前推荐的急性非静脉性上消化道出血患者的内镜疗法。
{"title":"Ideal strategy for nonvariceal upper gastrointestinal bleeding.","authors":"Robert T Kavitt, Ian M Gralnek","doi":"10.1097/MOG.0000000000001043","DOIUrl":"10.1097/MOG.0000000000001043","url":null,"abstract":"<p><strong>Purpose of review: </strong>Over 300 000 hospital admissions in the United States each year are due to patients with upper gastrointestinal (GI) bleeding (UGIB). Common etiologies of nonvariceal UGIB include peptic ulcers, mucosal erosions of the esophagus, stomach or duodenum, Mallory-Weiss tears, Dieulafoy lesions, upper GI tract malignancy, or other etiology.</p><p><strong>Recent findings: </strong>Peptic ulcers classified as Forrest Ia, Ib, or IIa require endoscopic hemostasis, while IIb ulcers may be considered for endoscopic clot removal with endoscopic treatment of any underlying major stigmata. Endoscopic hemostasis for ulcers classified as Forrest IIc or III is not advised due to the low risk of recurrent bleeding. Endoscopic hemostasis in ulcer bleeding can be achieved using injection, thermal, and/or mechanical modalities.</p><p><strong>Summary: </strong>This review focuses on the currently recommended endoscopic therapies of patients presenting with acute nonvariceal upper gastrointestinal hemorrhage.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"342-347"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction to the issue: acute pancreatitis and related metabolic complications. 本期简介:急性胰腺炎及相关代谢并发症。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/MOG.0000000000001044
Dhiraj Yadav, Phil A Hart, Melena Bellin
{"title":"Introduction to the issue: acute pancreatitis and related metabolic complications.","authors":"Dhiraj Yadav, Phil A Hart, Melena Bellin","doi":"10.1097/MOG.0000000000001044","DOIUrl":"10.1097/MOG.0000000000001044","url":null,"abstract":"","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"40 5","pages":"379-380"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future microbiome-based therapies in inflammatory bowel disease. 基于微生物组的炎症性肠病疗法的现状与未来。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-04-10 DOI: 10.1097/MOG.0000000000001027
Jonathan A Montrose, Satya Kurada, Monika Fischer

Purpose of review: The role of the microbiome and dysbiosis is increasingly recognized in the pathogenesis of inflammatory bowel disease (IBD). Intestinal microbiota transplant (IMT), previously termed fecal microbiota transplant has demonstrated efficacy in restoring a healthy microbiome and promoting gut health in recurrent Clostridioides difficile infection. Several randomized trials (RCTs) highlighted IMT's potential in treating ulcerative colitis, while smaller studies reported on its application in managing Crohn's disease and pouchitis.

Recent findings: This review delves into the current understanding of dysbiosis in IBD, highlighting the distinctions in the microbiota of patients with IBD compared to healthy controls. It explores the mechanisms by which IMT can restore a healthy microbiome and provides a focused analysis of recent RCTs using IMT for inducing and maintaining remission in IBD. Lastly, we discuss the current knowledge gaps that limit its widespread use.

Summary: The body of evidence supporting the use of IMT in IBD is growing. The lack of a standardized protocol impedes its application beyond clinical trials. Further research is needed to identify patient profile and disease phenotypes that benefit from IMT, to delineate key donor characteristics, optimize the delivery route, dosage, and frequency.

综述的目的:微生物组和菌群失调在炎症性肠病(IBD)发病机制中的作用日益得到认可。肠道微生物群移植(IMT),以前被称为粪便微生物群移植,已证明在复发性艰难梭菌感染中具有恢复健康微生物群和促进肠道健康的功效。几项随机试验(RCT)强调了 IMT 在治疗溃疡性结肠炎方面的潜力,而较小规模的研究则报道了 IMT 在治疗克罗恩病和肠袋炎方面的应用:本综述深入探讨了目前对 IBD 中菌群失调的认识,强调了 IBD 患者的微生物群与健康对照组的区别。综述探讨了IMT恢复健康微生物群的机制,并重点分析了近期使用IMT诱导和维持IBD缓解的临床试验。最后,我们讨论了目前限制其广泛应用的知识差距。摘要:支持在 IBD 中使用 IMT 的证据越来越多。缺乏标准化方案阻碍了其在临床试验之外的应用。需要开展进一步的研究,以确定从 IMT 中获益的患者特征和疾病表型,明确关键供体特征,优化给药途径、剂量和频率。
{"title":"Current and future microbiome-based therapies in inflammatory bowel disease.","authors":"Jonathan A Montrose, Satya Kurada, Monika Fischer","doi":"10.1097/MOG.0000000000001027","DOIUrl":"10.1097/MOG.0000000000001027","url":null,"abstract":"<p><strong>Purpose of review: </strong>The role of the microbiome and dysbiosis is increasingly recognized in the pathogenesis of inflammatory bowel disease (IBD). Intestinal microbiota transplant (IMT), previously termed fecal microbiota transplant has demonstrated efficacy in restoring a healthy microbiome and promoting gut health in recurrent Clostridioides difficile infection. Several randomized trials (RCTs) highlighted IMT's potential in treating ulcerative colitis, while smaller studies reported on its application in managing Crohn's disease and pouchitis.</p><p><strong>Recent findings: </strong>This review delves into the current understanding of dysbiosis in IBD, highlighting the distinctions in the microbiota of patients with IBD compared to healthy controls. It explores the mechanisms by which IMT can restore a healthy microbiome and provides a focused analysis of recent RCTs using IMT for inducing and maintaining remission in IBD. Lastly, we discuss the current knowledge gaps that limit its widespread use.</p><p><strong>Summary: </strong>The body of evidence supporting the use of IMT in IBD is growing. The lack of a standardized protocol impedes its application beyond clinical trials. Further research is needed to identify patient profile and disease phenotypes that benefit from IMT, to delineate key donor characteristics, optimize the delivery route, dosage, and frequency.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"40 4","pages":"258-267"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory bowel diseases 2024. 2024 年炎症性肠病。
IF 2.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-06 DOI: 10.1097/MOG.0000000000001038
Matthew A Ciorba
{"title":"Inflammatory bowel diseases 2024.","authors":"Matthew A Ciorba","doi":"10.1097/MOG.0000000000001038","DOIUrl":"10.1097/MOG.0000000000001038","url":null,"abstract":"","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"40 4","pages":"233-234"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small bowel intussusception - aetiology & management. 小肠肠套叠--病因和治疗。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-28 DOI: 10.1097/MOG.0000000000000994
Nicole Sciberras, Stefania Chetcuti Zammit, Reena Sidhu

Purpose of review: Adult small bowel intussusception (SBI) differs in incidence, symptomatology and management from the more commonly encountered paediatric intussusception. This review spans across the multitude of causes of adult SBI, and summarises the diagnostic work-up and management options according to recent literature.

Recent findings: There has been an increase in use of small bowel capsule endoscopy and point-of-care ultrasound for the diagnosis of acute adult SBI.

Summary: A high degree of suspicion of a malignant cause of SBI is required in the adult population. Alarm clinical features include weight loss, history of malignancy, and iron deficiency anaemia. CT remains the gold standard imaging technique as it may identify the lead point and thus aid in endoscopic or surgical management. If malignancy is excluded and no lead point is identified, serology and histology may be helpful to look for inflammatory, infective and autoimmune aetiology.

审查目的:成人小肠肠套叠(SBI)在发病率、症状学和处理方法上与更常见的儿科肠套叠有所不同。本综述涵盖了成人 SBI 的多种病因,并根据最新文献总结了诊断工作和治疗方案:小结:在成人人群中,需要高度怀疑 SBI 的恶性病因。警示性临床特征包括体重减轻、恶性肿瘤病史和缺铁性贫血。CT 仍是金标准成像技术,因为它可以确定导联点,从而有助于内镜或手术治疗。如果排除了恶性肿瘤且未发现导联点,血清学和组织学检查可能有助于寻找炎症、感染和自身免疫病因。
{"title":"Small bowel intussusception - aetiology & management.","authors":"Nicole Sciberras, Stefania Chetcuti Zammit, Reena Sidhu","doi":"10.1097/MOG.0000000000000994","DOIUrl":"10.1097/MOG.0000000000000994","url":null,"abstract":"<p><strong>Purpose of review: </strong>Adult small bowel intussusception (SBI) differs in incidence, symptomatology and management from the more commonly encountered paediatric intussusception. This review spans across the multitude of causes of adult SBI, and summarises the diagnostic work-up and management options according to recent literature.</p><p><strong>Recent findings: </strong>There has been an increase in use of small bowel capsule endoscopy and point-of-care ultrasound for the diagnosis of acute adult SBI.</p><p><strong>Summary: </strong>A high degree of suspicion of a malignant cause of SBI is required in the adult population. Alarm clinical features include weight loss, history of malignancy, and iron deficiency anaemia. CT remains the gold standard imaging technique as it may identify the lead point and thus aid in endoscopic or surgical management. If malignancy is excluded and no lead point is identified, serology and histology may be helpful to look for inflammatory, infective and autoimmune aetiology.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"175-182"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Terlipressin for hepatorenal syndrome. 治疗肝肾综合征的特利加压素
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-07 DOI: 10.1097/MOG.0000000000001016
Florence Wong

Purpose of review: The definition and diagnostic criteria of hepatorenal syndrome-acute kidney injury (HRS-AKI) has undergone recent changes. A major vasoconstrictor, terlipressin, has recently been approved as pharmacotherapy for HRS-AKI in the United States. The purpose of this review is to familiarize the readers with these new diagnostic criteria of HRS-AKI, and how best to use terlipressin.

Recent findings: Terlipressin is effective either as bolus dosing or continuous infusion and can achieve reversal of HRS-AKI in approximately 40% of patients. Continuous infusion allows lower daily dose with equal efficacy and less side effects but not an approved mode of administration in the United States. Response to terlipressin in the randomized controlled trials was defined as repeat reduction of serum creatinine to less than 1.5 mg/dl. Newer studies will likely require response to treatment to be defined as a repeat serum creatinine to be less than 0.3 mg/dl from baseline. Terlipressin use is associated with ischemic side effects and potential for respiratory failure development.

Summary: Careful patient selection and close monitoring are necessary for its use. Response to terlipressin with HRS-AKI reversal is associated with improved outcomes with better survival and less requirement for renal replacement therapy.

回顾的目的:肝肾综合征-急性肾损伤(HRS-AKI)的定义和诊断标准最近发生了变化。美国最近批准了一种主要的血管收缩剂特利加压素作为治疗 HRS-AKI 的药物疗法。本综述旨在让读者熟悉 HRS-AKI 的新诊断标准,以及如何更好地使用特利加压素:特利加压素通过栓剂给药或持续输注均有效,可逆转约 40% 的患者的 HRS-AKI。持续输注可降低每日剂量,但疗效相同且副作用较小,但在美国尚未获得批准。随机对照试验中对特利加压素的反应是指血清肌酐再次降至 1.5 mg/dl 以下。新的研究可能会要求将治疗反应定义为血清肌酐从基线再次降至 0.3 毫克/分升以下。使用特利加压素会产生缺血性副作用,并可能导致呼吸衰竭。使用特利加压素可逆转 HRS-AKI,改善预后,提高生存率,减少肾脏替代治疗的需求。
{"title":"Terlipressin for hepatorenal syndrome.","authors":"Florence Wong","doi":"10.1097/MOG.0000000000001016","DOIUrl":"10.1097/MOG.0000000000001016","url":null,"abstract":"<p><strong>Purpose of review: </strong>The definition and diagnostic criteria of hepatorenal syndrome-acute kidney injury (HRS-AKI) has undergone recent changes. A major vasoconstrictor, terlipressin, has recently been approved as pharmacotherapy for HRS-AKI in the United States. The purpose of this review is to familiarize the readers with these new diagnostic criteria of HRS-AKI, and how best to use terlipressin.</p><p><strong>Recent findings: </strong>Terlipressin is effective either as bolus dosing or continuous infusion and can achieve reversal of HRS-AKI in approximately 40% of patients. Continuous infusion allows lower daily dose with equal efficacy and less side effects but not an approved mode of administration in the United States. Response to terlipressin in the randomized controlled trials was defined as repeat reduction of serum creatinine to less than 1.5 mg/dl. Newer studies will likely require response to treatment to be defined as a repeat serum creatinine to be less than 0.3 mg/dl from baseline. Terlipressin use is associated with ischemic side effects and potential for respiratory failure development.</p><p><strong>Summary: </strong>Careful patient selection and close monitoring are necessary for its use. Response to terlipressin with HRS-AKI reversal is associated with improved outcomes with better survival and less requirement for renal replacement therapy.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"156-163"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139730866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative small bowel Crohn's disease: how to diagnose, manage and treat. 术后小肠克罗恩病:如何诊断、管理和治疗。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-01-31 DOI: 10.1097/MOG.0000000000001007
Chak Lam Ip, Ray Boyapati, Rahul Kalla

Purpose of review: Crohn's disease is a relapsing inflammatory condition and disease recurrence after surgery is common. Significant variation in clinical practice remains despite progress in management of postoperative Crohn's disease. In this review, we summarise current management strategies and guidelines, unmet needs, and research progress in this field.

Recent findings: There has been real progress in risk stratifying individuals' postsurgery and tailoring therapies based on their risk; this has been incorporated into current management guidelines in the USA, UK, and Europe. Furthermore, novel noninvasive monitoring tools such as intestinal ultrasound have shown high sensitivity and specificity at detecting disease recurrence and are an attractive point-of-care test. Recent studies are also investigating multiomic biomarkers to prognosticate postoperative Crohn's disease. However, given the heterogeneity within this condition, large multicentre clinical validation across all age groups is needed for clinical translation in the future.

Summary: Ongoing progress in research and the development of novel prognostic and noninvasive disease monitoring tools offers hope for personalised therapy tailored to individual recurrence risk in postoperative Crohn's disease.

审查目的:克罗恩病是一种复发性炎症,术后复发很常见。尽管术后克罗恩病的治疗取得了进展,但临床实践中仍存在很大差异。在这篇综述中,我们总结了当前的管理策略和指南、尚未满足的需求以及该领域的研究进展:最近的研究结果:在对术后患者进行风险分层并根据其风险量身定制治疗方法方面取得了真正的进展;这已被纳入美国、英国和欧洲目前的管理指南中。此外,新型无创监测工具(如肠道超声)在检测疾病复发方面显示出较高的灵敏度和特异性,是一种极具吸引力的护理点检测方法。最近的研究还在调查多组生物标志物,以预测术后克罗恩病的预后。小结:研究的不断进步以及新型预后和无创疾病监测工具的开发,为针对术后克罗恩病个体复发风险的个性化治疗带来了希望。
{"title":"Postoperative small bowel Crohn's disease: how to diagnose, manage and treat.","authors":"Chak Lam Ip, Ray Boyapati, Rahul Kalla","doi":"10.1097/MOG.0000000000001007","DOIUrl":"10.1097/MOG.0000000000001007","url":null,"abstract":"<p><strong>Purpose of review: </strong>Crohn's disease is a relapsing inflammatory condition and disease recurrence after surgery is common. Significant variation in clinical practice remains despite progress in management of postoperative Crohn's disease. In this review, we summarise current management strategies and guidelines, unmet needs, and research progress in this field.</p><p><strong>Recent findings: </strong>There has been real progress in risk stratifying individuals' postsurgery and tailoring therapies based on their risk; this has been incorporated into current management guidelines in the USA, UK, and Europe. Furthermore, novel noninvasive monitoring tools such as intestinal ultrasound have shown high sensitivity and specificity at detecting disease recurrence and are an attractive point-of-care test. Recent studies are also investigating multiomic biomarkers to prognosticate postoperative Crohn's disease. However, given the heterogeneity within this condition, large multicentre clinical validation across all age groups is needed for clinical translation in the future.</p><p><strong>Summary: </strong>Ongoing progress in research and the development of novel prognostic and noninvasive disease monitoring tools offers hope for personalised therapy tailored to individual recurrence risk in postoperative Crohn's disease.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"209-216"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on ischemic hepatitis. 缺血性肝炎的最新进展。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-15 DOI: 10.1097/MOG.0000000000001017
Jessica Elizabeth Smith, Don C Rockey

Purpose of review: Ischemic hepatitis (IH) refers to diffuse liver injury secondary to hypoperfusion. The condition is usually seen in the critical care setting and is associated with significant mortality. IH typically occurs in the setting of systemic hypotension superimposed on some form of underlying cardiac dysfunction. This review aims to report what is known and what is new about the etiology, pathophysiology, and clinical features associated with IH.

Recent findings: In recent years, studies on IH have largely confirmed earlier reports regarding etiologies, comorbid conditions, and associated mortality. Recent study has also shed light on the potential treatment of IH with N -acetyl-cysteine (NAC).

Summary: IH is typically associated with underlying cardiac disease, and patients with IH have a very high mortality rate. Treatment remains largely supportive, although the utility of agents such as NAC are being explored.

审查目的:缺血性肝炎(IH)是指继发于低灌注的弥漫性肝损伤。这种情况通常出现在重症监护环境中,死亡率很高。缺血性肝炎通常发生在全身性低血压叠加某种形式的潜在心脏功能障碍的情况下。本综述旨在报告与 IH 相关的病因学、病理生理学和临床特征方面的已知和新发现:近年来,有关 IH 的研究在很大程度上证实了之前有关病因、合并症和相关死亡率的报道。最近的研究还揭示了用 N-乙酰半胱氨酸(NAC)治疗 IH 的可能性。摘要:IH 通常与潜在的心脏疾病相关,IH 患者的死亡率非常高。虽然目前正在探索 NAC 等药物的效用,但治疗方法仍以支持疗法为主。
{"title":"Update on ischemic hepatitis.","authors":"Jessica Elizabeth Smith, Don C Rockey","doi":"10.1097/MOG.0000000000001017","DOIUrl":"10.1097/MOG.0000000000001017","url":null,"abstract":"<p><strong>Purpose of review: </strong>Ischemic hepatitis (IH) refers to diffuse liver injury secondary to hypoperfusion. The condition is usually seen in the critical care setting and is associated with significant mortality. IH typically occurs in the setting of systemic hypotension superimposed on some form of underlying cardiac dysfunction. This review aims to report what is known and what is new about the etiology, pathophysiology, and clinical features associated with IH.</p><p><strong>Recent findings: </strong>In recent years, studies on IH have largely confirmed earlier reports regarding etiologies, comorbid conditions, and associated mortality. Recent study has also shed light on the potential treatment of IH with N -acetyl-cysteine (NAC).</p><p><strong>Summary: </strong>IH is typically associated with underlying cardiac disease, and patients with IH have a very high mortality rate. Treatment remains largely supportive, although the utility of agents such as NAC are being explored.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"143-147"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal grade opium tincture for severe diarrhea: effect revisited in observational study. 药用鸦片酊治疗严重腹泻:观察性研究中的疗效回顾。
IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2023-10-26 DOI: 10.1097/MOG.0000000000000985
David Dahlgren, Per M Hellström

Purpose of review: Chronic diarrhea is a common disorder that interferes with normal daily activities and results in poor quality of life. Fecal urgency and incontinence often necessitate clinical consultation, but the pathophysiological mechanisms are difficult to differentiate in a clinical setting. Therefore, drugs targeting the opioid receptors, such as diphenoxylate and loperamide, are typically used, as they reduce both gut motility and secretion.

Recent findings: For severe diarrhea, morphine-containing extemporaneous opium tincture drops have recently been reprofiled to a pharmaceutical. The drug is indicated for severe diarrhea in adults when other antidiarrheals do not give sufficient fecal emptying control. The pronounced effect is due to the liquid formulation with rapid onset as a drug dissolution step is avoided. A recent prospective, noninterventional study (CLARIFY) of patients treated with opioid drops demonstrates a rapid and sustained therapeutic effect. Tolerance does not develop for the antidiarrheal effect and no dependence was observed after discontinuation.

Summary: This mini-review discusses the use of opium derivates for treatment of diarrhea, with an emphasis on opium drops as a new medicinal grade opium for the use as additional treatment of severe diarrhea, emphasizing its mechanism of action and evaluation of the risk-benefit ratio in the clinical setting.

综述目的:慢性腹泻是一种常见的疾病,干扰正常的日常活动,导致生活质量低下。排便紧迫和失禁通常需要临床咨询,但其病理生理机制在临床环境中很难区分。因此,通常使用靶向阿片受体的药物,如二苯氧基酯和洛哌丁胺,因为它们会降低肠道运动和分泌。最近的发现:对于严重腹泻,含有吗啡的临时鸦片酊滴剂最近被重新配制成一种药物。当其他止泻药物不能充分控制粪便排空时,该药物适用于成人严重腹泻。显著的效果是由于避免了药物溶解步骤,因此液体制剂起效快。最近一项针对阿片类药物滴剂治疗患者的前瞻性非干预性研究(CLARIFY)显示了快速和持续的治疗效果。止泻作用的耐受性没有发展,停药后也没有观察到依赖性。摘要:这篇小型综述讨论了鸦片衍生物治疗腹泻的用途,重点介绍了鸦片滴剂作为一种新的药用级鸦片,用于严重腹泻的额外治疗,强调了其作用机制和在临床环境中的风险效益比评估。
{"title":"Medicinal grade opium tincture for severe diarrhea: effect revisited in observational study.","authors":"David Dahlgren, Per M Hellström","doi":"10.1097/MOG.0000000000000985","DOIUrl":"10.1097/MOG.0000000000000985","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic diarrhea is a common disorder that interferes with normal daily activities and results in poor quality of life. Fecal urgency and incontinence often necessitate clinical consultation, but the pathophysiological mechanisms are difficult to differentiate in a clinical setting. Therefore, drugs targeting the opioid receptors, such as diphenoxylate and loperamide, are typically used, as they reduce both gut motility and secretion.</p><p><strong>Recent findings: </strong>For severe diarrhea, morphine-containing extemporaneous opium tincture drops have recently been reprofiled to a pharmaceutical. The drug is indicated for severe diarrhea in adults when other antidiarrheals do not give sufficient fecal emptying control. The pronounced effect is due to the liquid formulation with rapid onset as a drug dissolution step is avoided. A recent prospective, noninterventional study (CLARIFY) of patients treated with opioid drops demonstrates a rapid and sustained therapeutic effect. Tolerance does not develop for the antidiarrheal effect and no dependence was observed after discontinuation.</p><p><strong>Summary: </strong>This mini-review discusses the use of opium derivates for treatment of diarrhea, with an emphasis on opium drops as a new medicinal grade opium for the use as additional treatment of severe diarrhea, emphasizing its mechanism of action and evaluation of the risk-benefit ratio in the clinical setting.</p>","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"196-202"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1